These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. New antiarrhythmic drugs for the treatment of atrial fibrillation. Castro A; Bianconi L; Santini M Pacing Clin Electrophysiol; 2002 Feb; 25(2):249-59. PubMed ID: 11916001 [No Abstract] [Full Text] [Related]
4. Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. Singh S J Interv Card Electrophysiol; 2004; 10 Suppl 1():71-6. PubMed ID: 14739742 [TBL] [Abstract][Full Text] [Related]
5. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Nattel S; Liu L; St-Georges D Cardiovasc Res; 1998 Mar; 37(3):627-35. PubMed ID: 9659446 [TBL] [Abstract][Full Text] [Related]
6. [Progress in the clinical use of anti-arrhythmic drugs (I)]. Li WZ Zhonghua Er Ke Za Zhi; 2003 Oct; 41(10):735-7. PubMed ID: 14731351 [No Abstract] [Full Text] [Related]
7. Azimilide for atrial fibrillation: clinical trial results and implications. Pritchett EL; Marcello SR Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716 [TBL] [Abstract][Full Text] [Related]
8. Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias. Reiffel JA J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):333-9. PubMed ID: 11907635 [No Abstract] [Full Text] [Related]
9. New advances in class III antiarrhythmic drug therapy. Sager PT Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203 [TBL] [Abstract][Full Text] [Related]
10. New advances in class III antiarrhythmic drug therapy. Sager PT Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660 [TBL] [Abstract][Full Text] [Related]
11. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. Pritchett EL; Page RL; Connolly SJ; Marcello SR; Schnell DJ; Wilkinson WE J Am Coll Cardiol; 2000 Sep; 36(3):794-802. PubMed ID: 10987602 [TBL] [Abstract][Full Text] [Related]
12. Pure class III agents for prevention of sudden cardiac death. Pratt CM J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S82-6. PubMed ID: 12950526 [TBL] [Abstract][Full Text] [Related]
13. Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Page RL; Tilsch TW; Connolly SJ; Schnell DJ; Marcello SR; Wilkinson WE; Pritchett EL; Circulation; 2003 Mar; 107(8):1141-5. PubMed ID: 12615792 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of azimilide and dofetilide in the dog right atrial enlargement model of atrial flutter. Restivo M; Hegazy M; El-Hamami M; Yin H; Caref EB; Assadi MA; Brooks RR; El-Sherif N J Cardiovasc Electrophysiol; 2001 Sep; 12(9):1018-24. PubMed ID: 11573691 [TBL] [Abstract][Full Text] [Related]
15. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation. Pritchett EL; Schulte MC; Schnell D; Marcello SR; Wilkinson WE; Page RL; Connolly SJ; J Clin Pharmacol; 2002 Apr; 42(4):388-94. PubMed ID: 11936563 [TBL] [Abstract][Full Text] [Related]
16. Clinical differences between the newer antiarrhythmic agents. Camm AJ Europace; 2000 Jul; 1 Suppl C():C16-22. PubMed ID: 11220520 [TBL] [Abstract][Full Text] [Related]
17. Oral class III antiarrhythmics: what is new? Khan MH Curr Opin Cardiol; 2004 Jan; 19(1):47-51. PubMed ID: 14688634 [TBL] [Abstract][Full Text] [Related]
18. Update on atrial fibrillation: part II. Savelieva I; Camm J Clin Cardiol; 2008 Mar; 31(3):102-8. PubMed ID: 18383050 [TBL] [Abstract][Full Text] [Related]